图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-014872 Size: 4 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-014843 Size: 6 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-014861 Size: 7 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-014838 Size: 6 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-014078 Size: 4 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-010509 Size: 7 KB 网页链接
$Karyopharm(KPTI)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001193125-23-041600 Act: 33 Size: 1 MB 网页链接
$Karyopharm(KPTI)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-23-041597 Act: 33 Size: 77 KB 网页链接
$Karyopharm(KPTI)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-23-003129 Act: 34 Size: 21 MB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001193125-23-040183 Act: 34 Size: 207 KB 网页链接